

LONG IDEAS 5/11/22

Stability Amid Volatility

We first made Colgate-Palmolive (CL: \$77/share) a Long Idea in March 2018. Since then, the stock is up 12% compared to a 48% gain for the S&P 500. Despite its underperformance, the stock still offers investors favorable risk/reward, especially amid the current market volatility. We think the stock is worth at least \$104/share today – a 35%+ upside. Our last report (May 2021) on Colgate is here.


Learn more about the best fundamental research

This report leverages our cutting-edge <u>Robo-Analyst technology</u> to deliver <u>proven-superior</u>¹ fundamental research and support more cost-effective fulfillment of the fiduciary duty of care.

Colgate's Stock Has Strong Long-term Upside Based on:

- the company's large share of the global toothpaste and manual toothbrush market
- the near-recession-proof resilience of Colgate's products
- the company's large distribution network
- expected long-term growth in the company's key markets
- the current price has 35% upside at consensus growth rates.

Figure 1: Long Idea Performance: From Date of Publication Through 5/10/2022



Sources: New Constructs, LLC

What's Working

Strong Global Brand and Distribution Network Support Revenue Growth: Colgate-Palmolive has strong brands and a vast distribution network that create a strong competitive advantage. According to the <u>Kantar Brand Footprint Survey</u>, Colgate products are in more than 60% of all global households and it is second only to Coca-Cola as the world's most chosen brand. Smaller competitors cannot match Colgate's distinctive brands,

¹ Our research utilizes our <u>Core Earnings</u>, a more reliable measure of profits, as proven in <u>Core Earnings: New Data & Evidence</u>, written by professors at Harvard Business School (HBS) & MIT Sloan and published in <u>The Journal of Financial Economics</u>.



distribution network, and retail shelf space. These advantages helped the company improve its organic sales 4% year-over-year (YoY) in 1Q22².

The company is well-positioned to continue its revenue growth throughout the remainder of 2022. The company's manufacturing and distribution are back to full capacity, and the company plans to increase advertising spending. Given these developments, Colgate increased its 2022 revenue guidance range from 4% to 5% at the midpoint.

Steady Cash Flows in Multiple Market Environments: Colgate's strong brand, extensive distribution network, and resilient demand for its products enable the company to generate consistent free cash flow (<u>FCF</u>). No matter the economic environment, oral care, soap, deodorant, and cleaning products are essential for everyday life and exhibit strong demand.

Colgate has generated positive FCF each year since 1998 (earliest available data). Over the past decade, Colgate generated \$24.7 billion (38% of market cap) in FCF, per Figure 2. Colgate's consistent cash flows make its stock a natural choice for investors looking for stability amidst economic uncertainty.




Figure 2: Colgate's Cumulative Free Cash Flow Since 2012

Sources: New Constructs, LLC and company filings

Colgate's Digital Transformation: Colgate is quickly developing a strong digital channel that will leverage the same manufacturing and distribution advantages its current channels enjoy. Colgate's <u>digital sales</u> grew 27% YoY in 2021 and comprised 13% of total sales. The company's improved online capabilities better prepare it to compete with the increased number of direct-to-consumer competitors in its end markets.

Colgate Is More Profitable Than Competitors: Colgate has the highest invested capital turns amongst its peers listed in Figure 3. High invested capital turns help the company deliver superior return on invested capital (ROIC) compared to competitors too. Colgate's ROIC of 17% is much higher than the market-cap weighted average of its peers at 12%.

² Colgate defines organic sales as net sales excluding, as applicable, the impact of foreign exchange, acquisitions and divestments.



Figure 3: Colgate Vs. Peers: NOPAT Margin, IC Turns & ROIC: TTM


Company	Ticker	NOPAT Margin	IC Turns	ROIC
Colgate-Palmolive Company	CL	17%	1.0	17%
Unilever PLC	UL	15%	0.9	13%
Church & Dwight Co, Inc.	CHD	16%	8.0	12%
Procter & Gamble Co.	PG	18%	0.7	12%
GlaxoSmithKline PLC	GSK	24%	0.5	11%
Peer Group Market-Cap Weighted Average		18%	0.7	12%

Sources: New Constructs, LLC and company filings

Pet Nutrition Is a Growth Driver: Over the TTM, Colgate's pet nutrition segment accounted for ~20% of total sales, and since 2016, pet nutrition has grown faster than the rest of the company's total sales. Looking ahead, <u>Grand View Research</u> forecasts the global pet food market to grow at a 4.4% CAGR through 2030.

Furthermore, added capacity from Colgate's newly acquired pet food <u>manufacturing facility</u> will support continued growth in Colgate's pet nutrition segment.

Figure 4: Pet Nutrition Revenue as Percent of Total Since 2016



Sources: New Constructs, LLC and company filings

GAAP Earnings Are Understated: Colgate is more profitable than investors realize. Colgate's GAAP earnings have fallen from \$2.7 billion in 2020 to \$2.0 billion TTM. However, the company's TTM <u>Core Earnings</u>, which measure the normalized operating profits of the business, of \$2.6 billion are much higher. Should GAAP earnings more closely reflect the company's Core Earnings in the future, its shares could move higher on an earnings surprise.

What's Not Working

Lagging Sales from North America and Europe in 1Q22: Colgate pushed through aggressive price increases to achieve strong 1Q22 organic sales growth in emerging markets, which grew 4.5% YoY in 1Q22. However, the company delayed raising prices in North America and Europe until the end of 1Q22. As a result, organic sales in North America rose just 0.5% YoY and organic sales in Europe fell 3% YoY. Management noted in its 1Q22 earnings call, that they're seeing "strong sales" from North America and Europe in April. Assuming demand remains strong, the price increases implemented at the end of the first quarter will flow through to profits in coming quarters.



Margins Are Falling: In its recent 1Q22 earnings call, Colgate's management admitted, "2022 is shaping up as a more difficult year than we anticipated with greater-than-expected increases in raw materials as you have seen from others, particularly fats and oils and logistics." Specifically, the company is experiencing a 60% YoY increase in the cost of fats and oils, which are used in each of its product segments. Colgate is also experiencing higher transportation costs. Freight rates from its manufacturing facilities in Mexico to its distribution facilities in the U.S. are 30% higher than in 2021.

Though revenue grew in 1Q21, rising costs affected the bottom line. Core Earnings fell from \$708 million in 1Q21 to \$646 million in 1Q22. Increased raw material and transportation costs are eating away at the company's gross margins and Colgate's net operating profit after tax (NOPAT) margin has fallen from 19% in 2019 (before the pandemic) to 17% over the TTM.

However, over the long term, we expect Colgate will effectively offset increased raw material and transportation costs with price increases. Rising inflation has likely created a more elastic pricing environment for Colgate's products as its competitors are forced to adjust their pricing upwards as well. Most importantly, Colgate's superior ROIC and operational efficiency position is to weather input price inflation and continue to generate free cash flow better than competitors.

Growth of Private Labels: A long-term challenge facing many consumer product companies is the growth of private label products. Consumers have grown increasingly accepting of private labels. The long-term shift toward private label products accelerated during the COVID-19 pandemic, which saw nearly 40% of <u>U.S.</u> <u>consumers</u> try new brands in the midst of widespread supply-chain problems. Many of these consumers continue to stick with the private-label products they chose during the pandemic.

However, Colgate is better positioned than most consumer product companies since its private label competition is largely limited to its hand soap and toothbrush markets.

Market Share Losses During the Pandemic: Though Colgate remains the largest global toothpaste and manual toothbrush provider, the company lost market share during the pandemic. Colgate's share of the global toothpaste market fell from 42% in 1Q19 to 39% in 1Q22, while the company's share of the global manual toothbrush market fell from 32% to 31% over the same time.

Though its market share has slightly fallen from pre-pandemic levels, Colgate's share of the global toothpaste and manual toothbrush market has remained unchanged since 1Q21. Additionally, in the U.S., Colgate's share of the manual toothbrush market rose from 42% in 1Q19 to 44% in 1Q22.

Geopolitical Risks: In response to the Russia/Ukraine conflict, Colgate suspended sales of all products in Russia except for "essential health and hygiene products for everyday use". In its <u>1Q22 10-Q</u>, Colgate states that its actions in response to the Russia/Ukraine conflict "have not had a material impact on our business." For reference, sales to Eurasia, constituted ~2% of total sales in 2021.

While the conflict in Ukraine could heighten the risk of more conflicts across the globe, Colgate's exposure to any singular country outside of the U.S. is limited. Approximately 70% of the company's sales were generated in more than 200 countries outside of the U.S. in 2021. The company's primary geopolitical risk is input costs, which is a risk shared by its competitors.

Stock Is Priced for Decline in Profits

Colgate's price-to-economic book value (<u>PEBV</u>) ratio is just 0.9, which means the market expects its profits to fall and permanently remain 10% below TTM levels. Below, we use <u>our reverse discounted cash flow (DCF) model</u> to analyze the expectations for future growth in cash flows baked into a couple of stock price scenarios for Colgate.

In the first scenario, we quantify the expectations baked into the current price. We assume:

- NOPAT margin remains at TTM levels of 17% (below five-year average of 19%) from 2022 2031, and
- revenue falls 1% (vs. 2022 2024 consensus estimate CAGR of 4%) compounded annually from 2022 to 2031.

In this <u>scenario</u>, Colgate's NOPAT falls 1% compounded annually through 2031, and the stock is worth \$77/share today – equal to the current price.

Shares Could Reach \$104 +




If we assume Colgate's:

- NOPAT margin remains at TTM levels of 17% from 2022 2031,
- revenue grows at a 4% CAGR from 2022 2024 (equal to consensus estimate CAGR from 2022 2026), and
- revenue grows by just 2% (vs. 3% CAGR over the past two decades) compounded annually from 2027 2031, then

the stock is worth \$104/share today – 35% above the current price. In this scenario, Colgate grows NOPAT by 2% compounded annually over the next 10 years. For reference, Colgate has grown NOPAT by 2% compounded annually over the past five years and 5% compounded over the past two decades. Should Colgate's NOPAT growth improve to historical levels, the stock has even more upside.

Figure 5: Colgate's Historical and Implied NOPAT: DCF Valuation Scenarios



Sources: New Constructs, LLC and company filings

This article originally published on May 11, 2022.

David Trainer, Kyle Guske II, and Matt Shuler receive no compensation to write about any specific stock, sector, style, or theme.

Follow us on Twitter, Facebook, LinkedIn, and StockTwits for real-time alerts on all our research.



It's Official: We Offer the Best Fundamental Data in the World

Many firms claim their research is superior, but none of them can prove it with independent studies from highly-respected institutions as we can. Three different papers from both the public and private sectors show:

- 1. Legacy fundamental datasets suffer from significant inaccuracies, omissions and biases.
- 2. Only our "novel database" enables investors to overcome these flaws and apply <u>reliable</u> fundamental data in their research.
- 3. Our proprietary measures of <u>Core Earnings</u> and <u>Earnings Distortion</u> materially improve stock picking and forecasting of profits.

Best Fundamental Data in the World

Forthcoming in <u>The Journal of Financial Economics</u>, a top peer-reviewed journal, <u>Core Earnings: New Data & Evidence</u> proves our Robo-Analyst technology overcomes material shortcomings in legacy firms' data collection processes to provide superior <u>fundamental data</u>, <u>earnings</u> models, and <u>research</u>. More <u>details</u>.

Key quotes from the paper:

- "[New Constructs'] *Total Adjustments* differs significantly from the items identified and excluded from Compustat's adjusted earnings measures. For example... 50% to 70% of the variation in *Total Adjustments* is not explained by *S&P Global's (SPGI) Adjustments* individually." pp. 14, 1st para.
- "A final source of differences [between New Constructs' and S&P Global's data] is due to data collection oversights...we identified cases where Compustat did not collect information relating to firms' income that is useful in assessing core earnings." pp. 16, 2nd para.

Superior Models

A top accounting firm features the superiority of our ROIC, NOPAT and Invested Capital research to Capital IQ & Bloomberg's in Getting ROIC Right. See the Appendix for direct comparison details.

Key quotes from the paper:

- "...an accurate calculation of ROIC requires more diligence than often occurs in some of the common, off-the-shelf ROIC calculations. Only by scouring the footnotes and the MD&A [as New Constructs does] can investors get an accurate calculation of ROIC." pp. 8, 5th para.
- "The majority of the difference...comes from New Constructs' machine learning approach, which leverages technology to calculate ROIC by applying accounting adjustments that may be buried deeply in the footnotes across thousands of companies." pp. 4, 2nd para.

Superior Stock Ratings

Robo-Analysts' stock ratings outperform those from human analysts as shown in this <u>paper</u> from Indiana's Kelley School of Business. Bloomberg features the paper here.

Key quotes from the paper:

- "the portfolios formed following the buy recommendations of Robo-Analysts earn abnormal returns that are statistically and economically significant." pp. 6, 3rd para.
- "Our results ultimately suggest that Robo-Analysts are a valuable, alternative information intermediary to traditional sell-side analysts." pp. 20, 3rd para.

Our mission is to provide the best fundamental analysis of public and private businesses in the world and make it affordable for all investors, not just Wall Street insiders.

We believe every investor deserves to know the whole truth about the profitability and valuation of any company they consider for investment. More details on our cutting-edge technology and how we use it are here.



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first two days after New Constructs issues a report on that security.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report. New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs. Copyright New Constructs, LLC 2003 through the present date. All rights reserved.